Related Experiment Video

Updated: Jul 7, 2025

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

7.5K

Mechanisms and Therapeutic Strategies for MAFLD Targeting TLR4 Signaling Pathways

Guanghui Ren1, Changchuan Bai2, Sitong Yi3

  • 1Department of Infectious Disease, Liver Disease Center of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, China, 18842664480@163.com.

Journal of Innate Immunity
|December 21, 2023
PubMed
Abstract

Insights

Metabolic-associated fatty liver disease (MAFLD) involves complex mechanisms, with Toll-like receptor 4 (TLR4) signaling driving progression. Targeting TLR4 offers potential therapeutic strategies for MAFLD.

Area of Science:

  • Hepatology and immunology research.
  • Focus on metabolic and inflammatory liver diseases.

Background:

  • Metabolic-associated fatty liver disease (MAFLD) is a prevalent chronic liver condition with complex, multifactorial causes.
  • Current treatment options for MAFLD are limited.
  • Toll-like receptors (TLRs), particularly TLR4, are implicated in MAFLD pathogenesis by activating innate immune responses.

Purpose of the Study:

  • To review the significant role of TLR4 signaling pathways in MAFLD progression.
  • To explore the connection between TLR4 and key MAFLD mechanisms like lipid metabolism, insulin resistance, oxidative stress, and gut microbiota dysbiosis.
  • To highlight potential therapeutic strategies targeting TLR4 for MAFLD treatment.

Main Methods:

  • Literature review summarizing current research on TLR4 signaling in MAFLD.
  • Analysis of the impact of TLR4 on metabolic disorders, inflammation, and gut health in MAFLD.
  • Identification and categorization of potential therapeutic interventions targeting TLR4.

Main Results:

  • TLR4 signaling exacerbates MAFLD by promoting lipid peroxidation, inflammation, insulin resistance, and gut dysbiosis.
  • TLR4 pathways are linked to both obese and lean MAFLD phenotypes.
  • Suppression of TLR4 signaling is a promising approach for MAFLD mitigation.

Conclusions:

  • TLR4 is a critical mediator in MAFLD pathogenesis, influencing lipid accumulation, insulin resistance, oxidative stress, and immune activation.
  • Targeting TLR4 signaling pathways presents a viable therapeutic avenue for MAFLD.
  • Potential treatments include plant extracts, traditional medicines, probiotics, pharmaceuticals, and lifestyle modifications.
Keywords:
Metabolic-associated fatty liver diseasePathogenesisTherapeutic strategyToll-like receptor 4

More Related Videos

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

12.4K
Using RNA-interference to Investigate the Innate Immune Response in Mouse Macrophages12:47

Using RNA-interference to Investigate the Innate Immune Response in Mouse Macrophages

Published on: November 3, 2014

11.6K

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.9K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.4K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
128
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
141
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K